ArticleInternational journal of women's health2025
The Relationship Between Serum Uric Acid and Gynecologic Cancer Risk: A Mendelian Randomization Study.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Uric Acid Levels and the Risk of Breast Cancer and Benign Breast Tumors: A Systematic Review and Meta-Analysis.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: High serum uric acid (UA) levels have been linked to cancer development through chronic inflammation and oxidative damage. Traditional epidemiological studies have shown inconsistent results regarding the relationship between uric acid and gynecological cancers. This study uses Mendelian randomization (MR) to explore the potential association between serum UA levels and various gynecological cancers. Methods: In this two-sample MR study, summary statistical data of the genome-wide association studies (GWASs) on serum UA levels were extracted from the UK Biobank (UKB), and those on gynecological cancers were obtained from the FinnGen consortium, the Epidemiology of Endometrial Cancer Consortium (E2C2), and the Ovarian Cancer Association Consortium (OCAC). Inverse variance weighted (IVW), weighted median, MR-Egger, weighted mode, MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO), and MR-Radial methods were utilized to investigate the bidirectional causal associations of serum UA levels with gynecological cancers. The evaluation indexes were odds ratios (ORs) and confidence intervals (CIs). Tests for horizontal pleiotropism and heterogeneity of instrumental variables (IVs) were performed, respectively using MR-Egger test and Cochran's Q statistics. In addition, leave-one-out and MR scatter plots were employed for sensitivity analyses. Results: IVW estimates suggested that serum UA levels elevated 1 unit had a potential causal association with higher odds of both cervical cancer (CC) (OR=1.147, 95% CI: 1.020-1.290) and invasive mucinous ovarian cancer (IMOC) (OR=1.199, 95% CI: 1.033-1.393). Also, endometrial carcinoma (EC) had a potential causal association with it (OR=1.012, 95% CI: 1.000-1.024). Additionally, sensitivity analyses showed the potential causal associations between UA and CC/IMOC were relatively robust. Conclusion: An elevated serum UA level had potential associations with CC and IMOC, whereas patients with EC should pay attention to it in clinical practice, which may reduce the potential risk of gynecological cancers. However, further evidence is needed to clarify the true relationships between UA and gynecological cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.